SciSparc Ltd., a clinical-stage pharmaceutical company, and Clearmind Medicine Inc., a biotech firm, have announced the publication of an international patent application for a novel Ibogaine combination therapy. The therapy aims to enhance safety and efficacy in treating mental health and addiction issues. The patent application, filed under the Patent Cooperation Treaty, represents a collaboration between the two companies, focusing on the combination of Ibogaine with N-Acylethanolamines, including Palmitoylethanolamide. Ibogaine is known for its potential in treating various substance use disorders. Clearmind has filed thirteen patents related to this collaboration, with filings in the U.S. and other global jurisdictions. SciSparc specializes in cannabinoid pharmaceuticals and is developing drugs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus. Clearmind is working on psychedelic-derived therapeutics for health problems like alcohol use disorder and holds nineteen patent families. The announcement was made on September 16, 2024, and the press release is incorporated by reference into SciSparc's SEC filings.

SciSparc Ltd., a clinical-stage pharmaceutical company, and Clearmind Medicine Inc., a biotech firm, have announced the publication of an international patent application for a novel Ibogaine combination therapy. The therapy aims to enhance safety and efficacy in treating mental health and addiction issues. The patent application, filed under the Patent Cooperation Treaty, represents a collaboration between the two companies, focusing on the combination of Ibogaine with N-Acylethanolamines, including Palmitoylethanolamide. Ibogaine is known for its potential in treating various substance use disorders. Clearmind has filed thirteen patents related to this collaboration, with filings in the U.S. and other global jurisdictions. SciSparc specializes in cannabinoid pharmaceuticals and is developing drugs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus. Clearmind is working on psychedelic-derived therapeutics for health problems like alcohol use disorder and holds nineteen patent families. The announcement was made on September 16, 2024, and the press release is incorporated by reference into SciSparc's SEC filings.